EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 ( COVID ‐19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill

Nadine M C Pouw, Tessa Noordermeer iD, Bianca Boxma-de Klerk, Erwin Birnie, Evert-Jan Wils, Simone Rauh, Gert-Jan Braunstahl, Sander Mol, Ellen M van der Zwan-van Beek

Journal of Clinical Laboratory Analysis · 2026-04 · 40 (7)

DOI: 10.1002/jcla.70193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 16.03.2026. Verfasst von Nadine M C Pouw und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Serum Amyloid A Protein. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Siemens Healthineers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As the disease course of coronavirus disease 2019 (COVID‐19) can change rapidly, clinically relevant prognostic biomarkers could facilitate clinical‐decision making. Prior research has shown that Serum Amyloid A (SAA) might serve as a prognostic biomarker in patients with COVID‐19. The aim of this study was to determine the discriminative ability of SAA, C‐reactive protein (CRP), ferritin, and procalcitonin (PCT) in patients with COVID‐19 to differentiate between those who remain moderately ill from patients who become severely ill within 7 days of hospitalization.

Methods

Blood samples and disease severity assessment were collected at day 1 (day of hospitalization), 3, 5, and 7 in a Dutch cohort of patients who were hospitalized for COVID‐19. Blood was analyzed for concentrations of SAA, CRP, ferritin, and PCT.

Results

133 patients were included in this study. No differences in concentration of SAA, CRP, ferritin, and PCT at time of hospitalization were observed in patients who remained moderately ill compared to patients who progressed to severe COVID‐19 within 7 days of hospitalization. ROC curve analysis revealed that SAA, CRP, ferritin, and PCT failed to discriminate patients who progressed to severe illness from those who remained moderately ill, with areas under the curve (AUC) of 0.461 for SAA, 0.500 for CRP, 0.528 for PCT, and 0.550 for ferritin.

Conclusion

Our study demonstrates that SAA, CRP, ferritin, and PCT levels at the time of hospitalization failed to discriminate between COVID‐19 patients who remain moderately ill and those who progress to severe disease within 7 days.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Serum Amyloid A ProteinHumansCOVID-19MaleFemaleBiomarkersSeverity of Illness IndexMiddle AgedC-Reactive ProteinFerritinsProcalcitoninAgedSARS-CoV-2PandemicsROC CurveAdult

Stichwörter der Autor:innen

COVID19SARS‐CoV‐2acute phase proteinsbiomarkerserum amyloid a

Substanzen

Serum Amyloid A ProteinBiomarkersC-Reactive ProteinFerritinsProcalcitonin

Autor:innen und Institutionen

  • Department of Clinical Chemistry, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
  • Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Genetics, University Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Science, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
  • Department of Intensive Care, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
  • Department of Pulmonology, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.

ORCID-Profile: Tessa Noordermeer

Förderung

  • Siemens Healthineers

Zitieren

APA

Pouw, N. M. C., Noordermeer, T., Klerk, B. B., Birnie, E., Wils, E. J., Rauh, S., Braunstahl, G. J., Mol, S., & van der Zwan-van Beek, E. M. (2026). The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 ( COVID ‐19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill. Journal of Clinical Laboratory Analysis, 40(7). https://doi.org/10.1002/jcla.70193

Vancouver

Pouw NMC, Noordermeer T, Klerk BB, Birnie E, Wils EJ, Rauh S, et al. The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 ( COVID ‐19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill. Journal of Clinical Laboratory Analysis. 2026;40(7). doi:10.1002/jcla.70193

BibTeX
@article{Pouw2026,
  author = {Pouw, Nadine M C and Noordermeer, Tessa and Klerk, Bianca Boxma-de and Birnie, Erwin and Wils, Evert-Jan and Rauh, Simone and Braunstahl, Gert-Jan and Mol, Sander and van der Zwan-van Beek, Ellen M},
  title = {The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 ( COVID ‐19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2026},
  volume = {40},
  number = {7},
  doi = {10.1002/jcla.70193}
}
Kostenlos starten →